ACTIVEIMMUNITY

Is an independent medical institution for purposes of research and bio-production in the field of antibiotic resistance and immune deficiencies.

ACTIVEIMMUNITY

Is based on a number of patented products and techniques belonging to Dr. Ionel Victor PATRASCU, MVD PhD., a leading expert in immunology research.

Dr. Ionel Victor PATRASCU M.D.V., Ph.D.

23 Patents

  • Faculty: Veterinary Medicine, Bucharest, Romania (1963)
  • Doctor of veterinary science (1972), Faculty of Veterinary Medicine
  • Senior Scientist (1991) Institute of Virusology Stefan S. Nicolau, Bucharest, Romania
  • Houghton Poultry Research Station, Hantington, England: 1967, 1969, 1971, 1972. SPF chicken and oncogenic viruses studies.
  • Departament of Poultry Diseases, Cornell University, Ithaca, New York, USA. (1970 – 1971) Oncogenic viruses and tissue cultures.
  • Poultry Laboratories, Davis, California, USA (1971). Marek Disease’s vaccine and tissue culture.
  • Faculty of Veterinary Medicine, Athens, Georgia (1980, 1984) SPF chikens and tissue cultures.
  • Faculty of Veterinary Medicine, Insitute of Veterinary Medicine, Rotterdam, Olanda (1976). Bovine Leukemia Virus, high antigen purification confirmatory assay (1976).
  • Depertament of Veterinary Medicine, Cornell University. Ithaca New York, USA. (1972, 1982, 1983, 1984). Human and chicken oncogenic viruses, cell cultures.
  • Pasteur Institute, Paris, France (1990). Human Immunodeficiency Virus (HIV), virus isolation and characterisation.
  • Department of Veterinary Medicine, Cornell University, Ithaca New York, USA (1993). Human Immunodeficiency Virus (HIV) pathogenicity in human animal cells.
  • Oncological Institute, SanFrancisco, California, USA (1991, 1992). Characterisation of Human Immunodeficiency Virus (HIV) isolates.
  • Center of Disease Control (CDC) Atlanta, Georgia, USA (1992). Outbreake of Romanian Pediatric AIDS.

ABOUT ACTIVEIMMUNITY

Benefits from scientific support of the most important personalities of the medical world in Romania and members of the Romanian Academy of Science.

WHY NOW? WHY US?

Modern medicine must be reconsidered

ACCORDING TO:

  • Environment
  • Genetic susceptibility
  • Immune status
  • Relationship mucous/skin
  • Interrelationship nervous/immune systems
  • Relationship between the cells and the body
  • Relationship between energy transfer and information

IN RELATION WITH:

  • Society
  • Medical international relationship
  • International tourism
  • Regional activity
  • Global interdisciplinary activities

NEW PATENT- 2017

COMPOSITION AND METHOD OF PREPARING AND EVALUATION OF A COMPLEX IMMUNOGEN I-SPGA FOR IMMUNOLOGICALLY ACTIVE PROTEINS PRODUCTION (IAPs)
  • New concept in prevention and treatment of infectious diseases and immune deficiency
  • New antigen structures
  • New immunogens: multi and poly
  • Standard active immunologic proteins
  • Personalized active immunologic proteins
  • Immunograma
PROGRESS IN HUMAN MEDICINE CONTRIBUTING TO RESEARCH AND PRODUCTION OF BIO-PHARMACEUTICAL PRODUCTS
  • IgY technology is a relatively new field within bio-pharmaceutical disciplines, which has begun to draw the attention of specialists more than two decades ago. Pioneering efforts come largely from Japan, the US and Canada.
  • Since the discovery of egg yolk antibodies, now called immunoglobulin Y (IgY), in the late 1800s, this process has been harnessed to produce antigen-specific yolk antibodies for numerous applications in the medical and research fields, including in areas such as diagnostics and proteomics.
  • For the first time, a new immunologically active proteins group (IAPs) was isolated and studied by Dr. I.V. Patrascu.
  • Now, we own four times as much biological material from the same source capable of acting in the body and some new proteins provide us with a wide range of new uses depending on their native or acquired structure and functions (biological vector, personalized biological vector, specific biological vector).
  • Controlled-size peptides of these proteins have enabled the production of nanogels and biological nanoproducts for internal and external use and largely open the gate of therapeutic access to parenteral administrations.
  • With the availability of IgY products and IAPs as functional food products delivered in the form of granules, tablets, solutions, the practical impact for use in human medicine has created interest in the biomedical sphere, and their widespread potential is only beginning to show.
  • Antibiotic resistance, immunosensence, autoimmune diseases are just some of the areas of applicability of new technologies.
IgY AND IAPs (IMMUNOLOGICALLY ACTIVE PROTEINS) – SOLUTIONS IN THE POST-ANTIBIOTIC ERA
  • Post-antibiotics era – in which common infections or minor injuries can kill – it’s far from being just an apocalyptic fantasy, it’s instead a very real possibility in the 21st century (WHO).
  • Antimicrobial resistance (AMR) is an increasingly serious threat to public health worldwide. Governments around the world are making substantial efforts to find solutions to a serious problem that threatens the achievements of modern medicine (WHO).
  • In this context, nosocomial infections are considered to be another enemy.
  • Immunoglobulins Y and immunoproteins IAPs represent a viable solution in the fight against antibiotic resistant microorganisms.
IMMUNOGERONTOLOGY AND IMMUNOSENESCENCE – NEW FIELDS OF APPLICABILITY OF IgY AND IAPs (IMMUNOLOGICALLY ACTIVE PROTEINS)
  • It is well documented that the decline in immunocompetence occurs with age or, rather, is related to the age of humans.
  • In this case, the immune system begins to lose some of its functions and can not respond quickly or efficiently to stimuli.
  • Alteration of the immune system in the elderly is generally regarded as a deterioration of immunity called immunosenescence.
  • I The use of IgY and IAPs immunomodulators by the elderly brings real benefits to maintaining health (as a therapeutic tool for the extension of the thymus functioning period after 65 years, but also for the immunological support of the body in its absence).
THE NEW GENERATION OF IMMUNOMODULATORS – INNOVATION IN THE TREATMENT OF AUTOIMMUNE DISEASES
  • Administration of IgY and IPAs -containing products, immunomodulators, biological vectors, anti-inflammatory embryonic proteins has proven to be a real success in the therapy of patients with psoriasis or epidermolysis bullosa.
  • Although the exact mechanism of psoriasis is still unclear, the implication of T cell-mediated cytokine expression in the etiology of psoriasis is becoming clearer.
  • The aim of modern treatment is to target such immune responses that lead to the formation of psoriatic plaques and psoriatic arthritis using selective immunomodulatory pharmacotherapy.

A NEW CONCEPT IN PREVENTION AND TREATMENT

  • ANTIBIOTIC RESISTANCE

  • URINARY INFECTIONS

  • EPIDERMOLYSIS BULLOSA

  • NOSOCOMIAL INFECTIONS

  • PSORIASIS VULGARIS

  • DIABETES

    akdnsalndajksndkasndkanknxandakjdjkas

OPPORTUNITIES FOR OUR TECHNOLOGY

NEW PATENT- 2017

COMPOSITION AND METHOD OF PREPARING AND EVALUATION OF A COMPLEX IMMUNOGEN I-SPGA FOR IMMUNOLOGICAL ACTIVE PROTEINS PRODUCTION (IAPs)
  • The invention relates to a composition of a new type of immunogenic preparation called I-spga which immunizes the chickens for obtaining immunologically active proteins – IVP (Ionel Victor Patrascu).
  • Immunologically active proteins – IVP can be used to develop a range of biological products indicated in the treatment of:
    • Sensitive or antibiotic resistant urinary tract infections in children and adults;
    • Digestive tract infections;
    • Other mucous membranes, tissues or organs infections;
    • Nosocomial infections;
    • Immune deficiencies;
    • Psoriasis;
    • Epidermolysis bullosa;
    • Other dermatitis;